Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03087058 · ClinicalTrials.gov registry record · Phase 2
Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia
A Phase 2 study, sponsored by Vifor Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03087058 is a Phase 2 study that was terminated before completion, run by Vifor Pharma. The registered enrollment target is 23 participants.
The verdict
NCT03087058, a Phase 2 study, was terminated before completion, sponsored by Vifor Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the change in serum potassium levels from start of treatment to Day 14, when patiromer is administered at different doses, once daily, in children 2 - \< 18 years of age with chronic kidney disease (CKD) and hyperkalemia (too much potassium in the blood). Another purpose of the study is to evaluate the safety and tolerability of patiromer in children 2 - \< 18 years of age with CKD and hyperkalemia.
Interventions
- DRUG Patiromer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2017-07-07 |
| Est. Completion | 2021-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03087058
The ClinicalTrials.gov registry entry for NCT03087058 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vifor Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patiromer is the first listed.
NCT03087058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03087058 about?
NCT03087058 is a clinical study titled "Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia". The purpose of this study is to evaluate the change in serum potassium levels from start of treatment to Day 14, when patiromer is administered at different doses, once daily, in children 2 - \< 18 years of age with chronic kidney disease (CKD) and hyperkalemia (too much potassium in the blood). Ano...
What is the current status of trial NCT03087058?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2017-07-07. Estimated completion is 2021-04-30.
What interventions are being tested in trial NCT03087058?
The interventions under investigation include: Patiromer (DRUG).
Who is sponsoring clinical trial NCT03087058?
This trial is sponsored by Vifor Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.